Economic Evaluation of Intravenous Immunoglobulin plus Corticosteroids for the Treatment of Steroid-Resistant Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Thailand

Bamrungsawad N 1 , Upakdee N 1 , Pratoomsoot C 2 , Sruamsiri R 3 , Dilokthornsakul P 1 , Dechanont S 1 Show all authors , Wu DB 4 , Dejthevaporn C 5 , Chaiyakunapruk N 6

Affiliations 

  • 1 Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand
  • 2 Faculty of Public Health, Naresuan University, Phitsanulok, Thailand
  • 3 Center of Pharmaceutical Outcomes Research, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand
  • 4 School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 46150, Bandar Sunway, Selangor, Malaysia
  • 5 Division of Neurology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
  • 6 Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand. nathorn.chaiyakunapruk@monash.edu
Clin Drug Investig, 2016 Jul;36(7):557-66.
PMID: 27113227 DOI: 10.1007/s40261-016-0401-3

Abstract

Intravenous immunoglobulin (IVIG) has been recommended for steroid-resistant chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The treatment, however, is very costly to healthcare system, and there remains no evidence of its economic justifiability. This study aimed to conduct an economic evaluation (EE) of IVIG plus corticosteroids in steroid-resistant CIDP in Thailand.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications